Share Print
Main content
Research news

Research on Alzheimer's disease and neurodegenerative diseases is steadily progressing. In this section you will find various news items that make up the current news in this field, in Switzerland and around the world.

Blood-based biomarkers for Alzheimer’s disease could greatly simplify diagnosis and reduce costs

Amyloid and tau blood-based biomarkers are highly correlated with the corresponding biomarkers used so far for the diagnosis of Alzheimer’s disease.

An action plan to prevent Alzheimer’s disease

As the population ages, the number of people with Alzheimer's disease in Europe will double by 2050A task force led by the UNIGE and the HUG is laying the foundations for a preventive protocol.

Lecanemab : results confirmed and approval for US market launch

Detailed results from the phase 3 clinical trial of lecanemab have been confirmed: although it does not stop the disease, the drug slows its progression. The Food and Drug Administration (FDA) has accepted the drug for marketing, following an accelerated application

Lecanemab effective against Alzheimer's disease - strong support for the toxic role of amyloid

The results of a global phase 3 clinical trial of lecanemab, a new treatment for Alzheimer's disease, have been published in a press release

Professor Jean-Marie Annoni retires

Professor Jean-Marie Annoni, co-chief physician of the Neurology Unit at the Fribourg Hospital, retired on 31 August 2022. .

The role of lipids in the development of Alzheimer’s disease

A European consortium coordinated by UNIGE shows how a mutation in the APOE protein changes the lipid transport in the brain and could promote the arise of Alzheimer’s disease.


Dernière mise à jour : 11/08/2022